

Diabetic Retinopathy Guideline Committee Meeting 4

Date: 7th September 2022
Location: Virtual Meeting via Zoom
Minutes: Final

Committee members present:	
Mike Burdon (Chair)	Present for all items
Amandeep Bedi	Present for all items
Philip Burgess	Present for all items
Rosalind Creer	Present for all items
Christiana Dinah	Present for items 3-8
Louis Savage	Present for all items
Bernadette Warren	Present for all items
Becky Wei Luo	Present for all items

In attendance:		
Astrid Aregui	Senior Medical Editor, NICE	Present for items 3-6
Catrina Charlton	Guideline Commissioning Manager	Present for item 2
Jenny Craven	Information Specialist, NICE	Present for items 1-4
Nicola Cunliffe	Project Manager, Guideline Development Team	Present for all items
Jaqueline Durkin	Administrator, Guideline Development Team	Present for item 1
Kathryn Hopkins	NICE Technical Adviser	Present for all items
Kirsty Luckham	Technical Analyst (Health Economics)	Present for all items
Hugh McGuire	Senior Tech Adviser, NICE International	Present for items 5-8
Syed Mohiuddin	Technical Adviser (Health Economics)	Present for all items
Hannah Tebbs	Technical Analyst (Health Economics)	Present for all items
Philip Williams	Resource Impact Lead, NICE	Present for all items
Dr, Anneza Yiallourou	University of Cyprus in partnership with NICE	Present for items 1-6
Ahmed Yousef	Technical Analyst, Guideline Development Team	Present for all items

Apologies:	
John Anderson	Committee Member
Yvonne Coalbran	Committee Member
Noemi Lois	Committee Member
Jenny Kendrick	Information Services, NICE
Diva Shah	Committee Member
Magdalena Watras	Medicines Lead, NICE

1. Welcome and DOIs for the meeting

The Chair welcomed the committee members and attendees to the 4th meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received, these are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that are not listed in the registry. No new interests were declared.

2. Health economic modelling discussion

The Chair introduced Kirsty Luckham and Hannah Tebbs, who led on the health economic modelling discussion.

3. Review question 6: What is the effectiveness of vitrectomy surgery alone, or in combination with other treatments for treating proliferative diabetic retinopathy and macular oedema?

- **Evidence review**
- **Economic evidence**

The Chair introduced Ahmed Yosef who presented the evidence review and health economic evidence on the effectiveness of vitrectomy surgery alone, or in combination with other treatments for treating proliferative diabetic retinopathy and macular oedema (RQ6) with Hannah Tebbs.

The committee had the opportunity to give feedback and ask questions.

4. Recommendations: Vitrectomy

The committee discussed the evidence presented and the recommendations were drafted for (RQ6).

5. Recap of previous recommendations: monitoring frequencies

The Chair introduced Kathryn Hopkins who recapped previous recommendations for monitoring frequencies with the committee. The committee had the opportunity to engage and give feedback.

6. Recap of previous recommendations: effectiveness of interventions for the prevention of progression of non-proliferative retinopathy

Kathryn Hopkins recapped the previous recommendations of the effectiveness of interventions for the prevention of progression of non-proliferative retinopathy with the committee. The committee had the opportunity to engage and give feedback.

7. Discussion – inclusion of bevacizumab in evidence reviews, economic model and potential recommendations

The Chair introduced Syed Mohiuddin, who led a discussion with Kathryn Hopkins on the inclusion of bevacizumab in evidence reviews, economic model and potential recommendations. The committee had the opportunity to engage and give feedback.

8. AOB, summary and next steps

The Chair confirmed the next meeting date, next steps and thanked those present for their contributions. The meeting concluded.